Development Pipeline

We are pursuing a broad and deep pipeline with the potential to address 80 percent of the world’s cancers by incidence. In addition to leveraging our internal research resources, we continually evaluate external early-stage assets that might enhance our pipeline and opportunities.

Solid Tumor Programs
Hematology Programs
More Information
Download PDF

Safety and efficacy have not been established for investigational products and/or uses.

aMay include: PD-1 mAb, LAG3 mAb, OX40 mAb, TIM3 mAb, HPK1 inhibitor.
bin combination with zanubrutinib.

†Trial is listed on clinicaltrials.gov, but may not have subjects enrolled.

1Ensem collaboration; BeiGene has global rights.
2DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights.
3Leads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China.
4Zymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand.
5Amgen collaboration; BeiGene has development and commercialization rights in China.

1L, first line; 2L, second line; 3L, third line; 4-1BB, tumor necrosis factor receptor superfamily member 9; ADC, antibody-drug conjugate; AML, acute myeloid leukemia; BC, breast cancer; BCL2, B-cell lymphoma 2; BP-ALL, B-cell precursor acute lymphoblastic leukemia; BsAb, bispecific antibody; BTC, biliary tract cancer; BTK, Bruton tyrosine kinase; CCR8, the C-C motif chemokine receptor 8; CD3, cluster of differentiation 3; CD16A, Fc receptor FcγRIIIa; CD19, cluster of differentiation 19; CD79B, cluster of differentiation 79B; CDAC, chimeric degradation activating compound; CDK2, cyclin-dependent kinase 2; CDK4, cyclin-dependent kinase 4; CEA, carcinoembryonic antigen; cHL, classical Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; CRC, colorectal cancer; DGKζ, diacylglycerol kinase ζ; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like ligand 3; EGFR, epidermal growth factor receptor; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; FGFR2b, fibroblast growth factor receptor 2, isoform IIIb; FL, follicular lymphoma; gBRCAm, germline BReast CAncer gene (BRCA) mutation; GC, gastric cancer; GEA, gastroesophageal adenocarcinomas; GEJC, gastroesophageal junction carcinoma; GI, gastrointestinal; GPC3, glypican-3; IL-15, interleukin-15; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor 2; HNSCC, head and neck squamous cell carcinoma; HPK1, hematopoietic progenitor kinase 1; IO, immunotherapy; IRAK4, interleukin-1 receptor-associated kinase 4; KRAS, Kirsten rat sarcoma virus; LA, locally advanced; mAb, monoclonal antibody; LAG3, lymphocyte activation gene 3; LS-SCLC, limited-stage small cell lung cancer; mAb, monoclonal antibody; MCL, mantle cell lymphoma; mCRPC, metastatic castration-resistant prostate cancer; MDS, myelodysplastic syndromes; MM, multiple myeloma; MSS, microsatellite stability; MTx, maintenance treatment; MUC1, mucin 1; MZL, marginal zone lymphoma; NPC, nasopharyngeal carcinoma; NonSq, non-squamous; NSCLC, non–small cell lung cancer; OX40, a member of the tumor necrosis factor (TNF) receptor family, also know as CD134; PARP 1/2, poly (ADP-ribose) polymerase 1 and 2; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PRMT5, protein arginine methyltransferase 5; PSOC, platinum-sensitive ovarian cancer; R/R, recurrent/refractory; SCLC, small cell lung cancer; SLL, small lymphocytic lymphoma; SMAC, second mitochondria-derived activator of caspase; STEAP1, six-transmembrane epithelial antigen of the prostate 1; Sq, squamous; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TN, treatment naive; TsAb, trispecific antibody; UBC, urothelial bladder cancer; UC, urothelial carcinoma; WM, Waldenström macroglobulinemia.

More Information

For additional clinical trial information please visit clinicaltrials.gov.

Anti-OX40 Mechanism of Action

CDK4 Inhibitor Mechanism of Action

PARP1 Mechanism of Action

Anti-TIGIT Mechanism of Action